CLOSED
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%
Home/Business/AstraZeneca India to Sell Bengaluru Site…

AstraZeneca India to Sell Bengaluru Site for ₹3,400 Cr

Business
By ThePip Desk•
Add as a preferred source on Google
Two construction workers in hard hats and vests review documents near a barbed-wire fence with a partially visible "AstraZeneca" sign.

Workers discuss plans near a fenced-off AstraZeneca site in Bengaluru, India.

Key Highlights

AstraZeneca Pharma India plans to sell its 64-acre Bengaluru site for ₹3,400 crore. Land monetisation strategy attracts developers like Sattva & RMZ.

AstraZeneca Pharma India is planning to sell its 64-acre site in Bengaluru, with expectations of fetching approximately ₹3,400 crore. This sale is part of the company’s broader strategy to monetise its land assets.

Several developers have shown interest in the land parcel, including the Sattva Group, Aurobindo Pharma, and RMZ. The company is divesting the property as part of a strategic move to streamline its assets and focus on its core pharmaceutical operations.

The potential sale of the Bengaluru site is expected to generate significant funds for AstraZeneca Pharma India, which can be reinvested into research and development, as well as other key business areas. The deal is anticipated to be finalised in the near future, pending regulatory approvals and final negotiations with interested parties.

AstraZenecaAurobindo PharmaBengaluruIndiaRMZSattva Group